HBM HLDGS LTD DL-000025 (6XY) - Total Assets
Based on the latest financial reports, HBM HLDGS LTD DL-000025 (6XY) holds total assets worth €500.26 Million EUR (≈ $584.85 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HBM HLDGS LTD DL-000025 - Total Assets Trend (2021–2025)
This chart illustrates how HBM HLDGS LTD DL-000025's total assets have evolved over time, based on quarterly financial data. Also see HBM HLDGS LTD DL-000025 market capitalisation for the company's overall valuation and market capitalisation.
HBM HLDGS LTD DL-000025 - Asset Composition Analysis
Current Asset Composition (December 2025)
HBM HLDGS LTD DL-000025's total assets of €500.26 Million consist of 89.1% current assets and 10.9% non-current assets. Review how much debt does HBM HLDGS LTD DL-000025 carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 80.3% |
| Accounts Receivable | €5.93 Million | 1.2% |
| Inventory | €6.38 Million | 1.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €7.67 Million | 1.5% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how HBM HLDGS LTD DL-000025's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest HBM HLDGS LTD DL-000025 stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HBM HLDGS LTD DL-000025's current assets represent 89.1% of total assets in 2025, an increase from 85.3% in 2021.
- Cash Position: Cash and equivalents constituted 80.3% of total assets in 2025, up from 76.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 1.5% of total assets.
HBM HLDGS LTD DL-000025 Competitors by Total Assets
Key competitors of HBM HLDGS LTD DL-000025 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.78 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
HBM HLDGS LTD DL-000025 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.17 | 2.82 | 3.45 |
| Quick Ratio | 5.10 | 2.79 | 3.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €359.65 Million | €126.66 Million | €144.16 Million |
HBM HLDGS LTD DL-000025 - Advanced Valuation Insights
This section examines the relationship between HBM HLDGS LTD DL-000025's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.75 |
| Latest Market Cap to Assets Ratio | 2.35 |
| Asset Growth Rate (YoY) | 132.7% |
| Total Assets | €500.26 Million |
| Market Capitalization | $1.17 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values HBM HLDGS LTD DL-000025's assets at a significant premium (2.35x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: HBM HLDGS LTD DL-000025's assets grew by 132.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for HBM HLDGS LTD DL-000025 (2021–2025)
The table below shows the annual total assets of HBM HLDGS LTD DL-000025 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €500.26 Million ≈ $584.85 Million |
+132.66% |
| 2024-12-31 | €215.01 Million ≈ $251.37 Million |
-5.89% |
| 2023-12-31 | €228.48 Million ≈ $267.12 Million |
-1.57% |
| 2022-12-31 | €232.12 Million ≈ $271.38 Million |
-17.79% |
| 2021-12-31 | €282.36 Million ≈ $330.11 Million |
-- |
About HBM HLDGS LTD DL-000025
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company i… Read more